Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Successful treatment of adult-onset Still's disease refractory to TNF and IL-1 blockade by IL-6 receptor blockade.

× No keyword cloud information.

15 in total

Review 1. Adult-Onset Still's Disease: Molecular Pathophysiology and Therapeutic Advances.

Authors: Paolo Sfriso; Sara Bindoli; Paola Galozzi
Journal: Drugs Date: 2018-08 Impact factor: 9.546

Review 2. Successful treatment of adult-onset Still's disease with tocilizumab monotherapy: two case reports and literature review.

Authors: Ryota Sakai; Hayato Nagasawa; Eiko Nishi; Ayumi Okuyama; Hirofumi Takei; Takahiko Kurasawa; Tsuneo Kondo; Koji Nishimura; Yuichiro Shirai; Tatsuya Ito; Hideto Kameda; Tsutomu Takeuchi; Koichi Amano
Journal: Clin Rheumatol Date: 2012-01-04 Impact factor: 2.980

3. Tocilizumab for the treatment of adult-onset Still's disease: results from a case series.

Authors: Paola Cipriani; Piero Ruscitti; Francesco Carubbi; Ilenia Pantano; Vasiliki Liakouli; Onorina Berardicurti; Roberto Giacomelli
Journal: Clin Rheumatol Date: 2013-09-05 Impact factor: 2.980

4. Tocilizumab for the treatment of rheumatoid arthritis and other systemic autoimmune diseases: current perspectives and future directions.

Authors: Atsushi Ogata; Toshio Tanaka
Journal: Int J Rheumatol Date: 2012-01-18

Review 5. Progress in Biological Therapies for Adult-Onset Still's Disease.

Authors: Paola Galozzi; Sara Bindoli; Andrea Doria; Paolo Sfriso
Journal: Biologics Date: 2022-04-21

Review 6. An Update on the Pathogenic Role of Macrophages in Adult-Onset Still's Disease and Its Implication in Clinical Manifestations and Novel Therapeutics.

Authors: Po-Ku Chen; Der-Yuan Chen
Journal: J Immunol Res Date: 2021-06-20 Impact factor: 4.818

Successful treatment of adult-onset Still's disease refractory to TNF and IL-1 blockade by IL-6 receptor blockade.

Review 1. Adult-Onset Still's Disease: Molecular Pathophysiology and Therapeutic Advances.

Review 2. Successful treatment of adult-onset Still's disease with tocilizumab monotherapy: two case reports and literature review.

3. Tocilizumab for the treatment of adult-onset Still's disease: results from a case series.

4. Tocilizumab for the treatment of rheumatoid arthritis and other systemic autoimmune diseases: current perspectives and future directions.

Review 5. Progress in Biological Therapies for Adult-Onset Still's Disease.

Review 6. An Update on the Pathogenic Role of Macrophages in Adult-Onset Still's Disease and Its Implication in Clinical Manifestations and Novel Therapeutics.

Review 7. Targeting interleukin-6: all the way to treat autoimmune and inflammatory diseases.

8. Adult Onset Still's Disease and Autoinflammation.

9. Adult-Onset Still's Disease: From Pathophysiology to Targeted Therapies.

Review 10. Tocilizumab in the treatment of the adult-onset Still's disease: current clinical evidence.